Lee Peplinski, OD
Optometrist · Louisville, KYNPI 1831173988
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $55,276 of the $73,606 with a category attached, or 75.1%. AbbVie accounts for 62.5% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2022 at $25,322 and has fallen 93.6% since, to $1,612 in 2025. Among optometrist clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 337 payments — averaging $218.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$46K
- Sun Pharmaceutical Industries Inc.$17K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$6K
- Glaukos Corporation$690
- Novartis$648
- Alcon$460
- plus $2K from 17 others
What the payments were for
- Consulting fees$4501%
- Speaking & faculty fees$55,27675%
- Travel & lodging$9,18412%
- Food & beverage$8,59012%
- Education$1070%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 108 | $46,008 |
| Sun Pharmaceutical Industries Inc. | 50 | $16,924 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 28 | $6,400 |
| Glaukos Corporation | 7 | $690 |
| Novartis | 54 | $648 |
| Alcon | 6 | $460 |
| Bausch & Lomb Americas Inc. | 13 | $459 |
| Rxsight Inc | 7 | $331 |
| Biotissue Holdings Inc. | 9 | $306 |
| Tarsus Pharmaceuticals, Inc. | 5 | $228 |
| Shire North American Group Inc | 8 | $194 |
| Aerie Pharmaceuticals, Inc. | 9 | $188 |
| Kala Pharmaceuticals, Inc. | 5 | $171 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $141 |
| Amgen(2 entities) | 7 | $129 |
| Oyster Point Pharma, Inc. | 3 | $58 |
| Thea Pharma Inc. | 3 | $48 |
| Ivantis, Inc | 3 | $45 |
| Mallinckrodt Hospital Products Inc. | 2 | $45 |
| Harrow Eye, LLC | 2 | $41 |
| Eyevance Pharmaceuticals LLC | 2 | $41 |
| Mallinckrodt Enterprises LLC | 1 | $26 |
| Dompe US, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DURYSTA$44,228
- CEQUA$15,660
- VYZULTA$5,707
- XIIDRA$368
- iDoseTR$308
- iStent Infinite$179
- Photrexa Viscous and Photrexa$150
- RXSIGHT CONTACT LENS$135
- RXSIGHT INJECTOR CARTRIDGE$135
- RXSIGHT INJECTOR HANDPIECE$135
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$135
- LIGHT ADJUSTABLE LENS (LAL)$135
- LUMIGAN$134
- ACTIVEFOCUS$127
- ReSTOR$125
- XDEMVY$125
- RESTASIS$124
- XEN$124
- MIEBO$123
- TRYPTYR$122
How this compares
$73,606 in reported general payments places this provider in the 95th percentile of 712 optometrist providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 18 | $23,932 |
| LumiganBimatoprost | 20 | $11,514 |
| CombiganBrimonidine Tartrate/Timolol | 20 | $6,149 |
| EysuvisLoteprednol Etabonate | 12 | $5,714 |
| Fluorometholone | 60 | $5,586 |
| Prednisolone Acetate | 86 | $4,156 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 22 | $2,824 |
| Loteprednol Etabonate | 22 | $2,730 |
| Bimatoprost | 16 | $2,169 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 92 | $1,646 |
| Latanoprost | 121 | $1,608 |
| Pilocarpine Hcl | 14 | $1,039 |
| ValacyclovirValacyclovir Hcl | 38 | $871 |
| Brimonidine Tartrate | 20 | $746 |
| Timolol Maleate | 41 | $510 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $46,008 | $41,59558 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $171 | $5,71412 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $6,400 | $2,73022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 712 optometrist providers in Kentucky.
Other optometrist in Louisville
- Austin LifferthLouisville$72K
- Aaron McNultyLouisville$22K
- Ian McWherterLouisville$18K
- Kevin SnipesLouisville$13K
- Richard ManganLouisville$12K
- Keith SlaydenLouisville$9K
- Benjamin PaxtonLouisville$8K
- Nikolaos ZagorianosLouisville$8K
- Fiona BoakLouisville$8K
- Rod RalloLouisville$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.